They showed an association between the upregulation of the IL-6/STAT3 signature and durable clinical remissions in CLL patients treated with CD19+ CAR T-cells [31] (hypothetical model: Fig. 1). Here, CD19 is linked to B-cell chronic lymphocytic leukemia.